91219-90-8

Basic information

• Product Name: 2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE
• Synonyms: 2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE;2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHY&;2-(Acetoxymethyl)-4-methylpyridine;(4-methoxy-3,5-dimethylpyridin-2-yl)methyl acetate
• CAS NO: 91219-90-8
• Molecular Formula: C₁₁H₁₅NO₃
• Molecular Weight: 209.24
• Product Categories: Heterocyclic Compounds;C9 to C46;Heterocyclic Building Blocks;Pyridines
• Mol File: 91219-90-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 45.5-49.5 °C(lit.)
• Boiling Point: 293.2±35.0 °C(Predicted)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.089±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 5.72±0.47(Predicted)
• CAS DataBase Reference: 2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE(91219-90-8)
• EPA Substance Registry System: 2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE(91219-90-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 91219-90-8(Hazardous Substances Data)

Usage

Description

2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE is a chemical compound with the molecular formula C11H15NO4. It is a derivative of pyridine, an important heterocyclic compound with a wide range of applications in various industries.

Uses

Used in Pharmaceutical Industry:
2-(ACETOXYMETHYL)-4-METHOXY-3,5-DIMETHYLPYRIDINE is used as an impurity in the synthesis of Esomeprazole Magnesium (E668300), an S-Form of Omeprazole (O635000). Esomeprazole Magnesium is a gastric proton-pump inhibitor, which helps in reducing the production of stomach acid, providing relief from heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).

Upstream product

• 109371-20-2 4-chloro-2,3,5-trimethylpyridine 1-oxide 
• 86604-80-0 4-methoxy-2,3,5-trimethylpyridine 1-oxide 
• 74409-42-0 2,3,5-trimethylpyridine 1-oxide 
• 86604-79-7 2,3,5-trimethyl-4-nitropyridine N-oxide 
• 108-24-7 acetic anhydride 
• 695-98-7 2,3,5-trimethyl-pyridine 

Downstream Products

• 86604-75-3 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride 
• 96300-88-8 2-Hydroxymethyl-4-methoxy-3,5-dimethylpyridine hydrochloride 
• 122332-68-7 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-6-(4-methoxy-phenyl)-3H-thieno[3,4-d]imidazole 
• 122307-88-4 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethylsulfanyl)-6-(4-methoxy-phenyl)-3H-thieno[3,4-d]imidazole 
• 122307-93-1 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-6-phenyl-3H-thieno[3,4-d]imidazole 
• 122307-85-1 2-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethylsulfanyl)-6-phenyl-3H-thieno[3,4-d]imidazole 
• 84006-10-0 (chloromethyl)-4-methoxy-3,5-dimethylpyridine 
• 86604-78-6 (4-methoxy-3,5-dimethylpyridin-2-yl)methanol 

Relevant articles and documents

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

Process for the preparation of 2-halomethyl-3,5-dimethyl-4-methoxypyridine halohydrate

The process comprises a first step of O-acylation and subsequent acyloxylation of the 2-position methyl group of 2,3,5-trimethyl-4-methoxypyridine N-oxide, to obtain a compound which is subjected to a final halogenation step, in which the 2-position substituent is converted into halomethyl with a halogenating agent.

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.